1. Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
- Author
-
Johansson, Annelie, Yu, Nancy Y, Iftimi, Adina, Tobin, Nicholas P, Veer, Laura 't, Nordenskjöld, Bo, Benz, Christopher C, Fornander, Tommy, Perez‐Tenorio, Gizeh, Stål, Olle, Esserman, Laura J, Yau, Christina, and Lindström, Linda S
- Subjects
Genetics ,Breast Cancer ,Clinical Research ,Cancer ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Biomarkers ,Tumor ,Breast Neoplasms ,Female ,Humans ,Phosphatidylinositol 3-Kinases ,Proto-Oncogene Proteins c-akt ,Receptor ,ErbB-2 ,Receptors ,Estrogen ,Receptors ,Progesterone ,TOR Serine-Threonine Kinases ,70-gene signature ,breast cancer ,gene expression ,long-term survival ,prognosis ,ultralow risk ,Receptor ,erbB-2 ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
The metastatic potential of estrogen receptor (ER)-positive breast cancers is heterogeneous and distant recurrences occur months to decades after primary diagnosis. We have previously shown that patients with tumors classified as ultralow risk by the 70-gene signature have a minimal long-term risk of fatal breast cancer. Here, we evaluate the previously unexplored underlying clinical and molecular characteristics of ultralow risk tumors in 538 ER-positive patients from the Stockholm tamoxifen randomized trial (STO-3). Out of the 98 ultralow risk tumors, 89% were luminal A molecular subtype, whereas 26% of luminal A tumors were of ultralow risk. Compared to other ER-positive tumors, ultralow risk tumors were significantly (Fisher's test, P
- Published
- 2022